# Dofetilide

Drug · id `cardio:dofetilide` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Tikosyn

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems  

## In plain language

Dofetilide, sold as Tikosyn, is a medicine taken by mouth that the US label describes as an antiarrhythmic drug with Vaughan Williams Class III activity; it blocks a potassium current in the heart. The label read lists two uses: the maintenance of normal sinus rhythm (delay in the time to recurrence of atrial fibrillation or flutter) in patients with atrial fibrillation or flutter of more than a week's duration who have been converted to normal sinus rhythm, and the conversion of atrial fibrillation and flutter to normal sinus rhythm. It says the medicine has not been shown to be effective when the atrial fibrillation is paroxysmal. The label carries a boxed warning about induced arrhythmia.

## Technical summary

RxNorm ingredient 49247 (dofetilide, no salt); UNII R4Z9X1N2ND (exact). MeSH has no descriptor for dofetilide (the exact-label descriptor lookup returned an empty list); the term dofetilide exists (T205355) but is not a descriptor, so no MeSH code was added. RxClass lists the FDA established pharmacologic class Antiarrhythmic, and the openFDA record of the label carries the same class (Antiarrhythmic \[EPC\]). The label read is the Pfizer Laboratories Div Pfizer Inc label for Tikosyn capsules, application NDA020931, effective 2026-04-21 in openFDA. Drugs@FDA also lists a generic product (ANDA210740) whose brand name is a misspelling of dofetilide; generic labels were not read. This page records label indications, the class, the mechanism sentence and the boxed warning only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: Patients starting or restarting Tikosyn, as described in a US label boxed warning

Recipient: Recipient not specified; Population: Patients who are started or restarted on the medicine, as the boxed warning describes them. The passages read give no age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The same US label carries a boxed warning about the risk of induced arrhythmia in patients who start or restart the medicine. The warning also names the setting in which treatment is to begin; that instruction is not repeated here.

- Category: Safety
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients who are started or restarted on the medicine, as the boxed warning describes them. The passages read give no age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records the subject of the label's boxed warning only. The warning goes on to say what prescribers must do when treatment starts or restarts, and the label gives dosing instructions; those instructions are not repeated here. Other warnings, contraindications and interactions were not recorded. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Supports: openFDA drug label record for Tikosyn (dofetilide capsules), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class, boxed warning (Regulator, edition The openFDA drug label record for set id 02438044-d6a3-49e9-a1ac-3aad21ef2c8c (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA020931), returned on 2026-11-18. The label text is dated 2026-04-21 (effective\_time). Other openFDA records of dofetilide labels from generic sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2202438044-d6a3-49e9-a1ac-3aad21ef2c8c%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], first sentence. Retrieved 2026-11-18T21:55:13Z. Source state: Current. Version fingerprint: 97ab27af79e27cab8a79d0efa2c5d04e23b5628ffa5f726f662d99a2cf79bbb3.
     How it applies: Label passage quoted in the research quote table (LB-11).
  2. Background: openFDA drug label record for Tikosyn (dofetilide capsules), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class, boxed warning (Regulator, edition The openFDA drug label record for set id 02438044-d6a3-49e9-a1ac-3aad21ef2c8c (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA020931), returned on 2026-11-18. The label text is dated 2026-04-21 (effective\_time). Other openFDA records of dofetilide labels from generic sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2202438044-d6a3-49e9-a1ac-3aad21ef2c8c%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T21:55:13Z. Source state: Current. Version fingerprint: 97ab27af79e27cab8a79d0efa2c5d04e23b5628ffa5f726f662d99a2cf79bbb3.
     How it applies: Effective date of the label text read, 20260421.

## Context: Patients with atrial fibrillation or flutter, as described in the US label of Tikosyn

Recipient: Recipient not specified; Population: Patients described in the indications section of the label: patients with atrial fibrillation or flutter of more than one week's duration who have been converted to normal sinus rhythm, and patients in atrial fibrillation or flutter for whom conversion to normal sinus rhythm is sought. The passages read do not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of Tikosyn (dofetilide capsules, Pfizer Laboratories Div Pfizer Inc, application NDA020931; the version dated 2026-04-21 in openFDA) lists the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation or flutter) in patients with atrial fibrillation or flutter of more than one week's duration who have been converted to normal sinus rhythm, and the conversion of atrial fibrillation and flutter to normal sinus rhythm. It states that the medicine has not been shown to be effective when the atrial fibrillation is paroxysmal.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients described in the indications section of the label: patients with atrial fibrillation or flutter of more than one week's duration who have been converted to normal sinus rhythm, and patients in atrial fibrillation or flutter for whom conversion to normal sinus rhythm is sought. The passages read do not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also says that, because the medicine can cause life-threatening ventricular arrhythmias, it should be reserved for patients whose atrial fibrillation or flutter is highly symptomatic; that is the label's statement, not the atlas's advice. Contraindications, other warnings, interactions, restricted-program requirements and dosing were not recorded. Generic dofetilide labels were not read. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-18
- Sources:
  1. Supports: openFDA drug label record for Tikosyn (dofetilide capsules), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class, boxed warning (Regulator, edition The openFDA drug label record for set id 02438044-d6a3-49e9-a1ac-3aad21ef2c8c (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA020931), returned on 2026-11-18. The label text is dated 2026-04-21 (effective\_time). Other openFDA records of dofetilide labels from generic sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2202438044-d6a3-49e9-a1ac-3aad21ef2c8c%22&limit=1>
     Locator: results\[0\].description\[0\], first sentence. Retrieved 2026-11-18T21:55:13Z. Source state: Current. Version fingerprint: 97ab27af79e27cab8a79d0efa2c5d04e23b5628ffa5f726f662d99a2cf79bbb3.
     How it applies: Label passage quoted in the research quote table (LB-04).
  2. Supports: openFDA drug label record for Tikosyn (dofetilide capsules), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class, boxed warning (Regulator, edition The openFDA drug label record for set id 02438044-d6a3-49e9-a1ac-3aad21ef2c8c (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA020931), returned on 2026-11-18. The label text is dated 2026-04-21 (effective\_time). Other openFDA records of dofetilide labels from generic sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2202438044-d6a3-49e9-a1ac-3aad21ef2c8c%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], maintenance of normal sinus rhythm. Retrieved 2026-11-18T21:55:13Z. Source state: Current. Version fingerprint: 97ab27af79e27cab8a79d0efa2c5d04e23b5628ffa5f726f662d99a2cf79bbb3.
     How it applies: Label passage quoted in the research quote table (LB-05, LB-06).
  3. Supports: openFDA drug label record for Tikosyn (dofetilide capsules), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class, boxed warning (Regulator, edition The openFDA drug label record for set id 02438044-d6a3-49e9-a1ac-3aad21ef2c8c (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA020931), returned on 2026-11-18. The label text is dated 2026-04-21 (effective\_time). Other openFDA records of dofetilide labels from generic sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2202438044-d6a3-49e9-a1ac-3aad21ef2c8c%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], conversion. Retrieved 2026-11-18T21:55:13Z. Source state: Current. Version fingerprint: 97ab27af79e27cab8a79d0efa2c5d04e23b5628ffa5f726f662d99a2cf79bbb3.
     How it applies: Label passage quoted in the research quote table (LB-07, LB-08).
  4. Background: openFDA drug label record for Tikosyn (dofetilide capsules), Pfizer Laboratories Div Pfizer Inc label: indications, mechanism, class, boxed warning (Regulator, edition The openFDA drug label record for set id 02438044-d6a3-49e9-a1ac-3aad21ef2c8c (manufacturer Pfizer Laboratories Div Pfizer Inc, application NDA020931), returned on 2026-11-18. The label text is dated 2026-04-21 (effective\_time). Other openFDA records of dofetilide labels from generic sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%2202438044-d6a3-49e9-a1ac-3aad21ef2c8c%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-18T21:55:13Z. Source state: Current. Version fingerprint: 97ab27af79e27cab8a79d0efa2c5d04e23b5628ffa5f726f662d99a2cf79bbb3.
     How it applies: Effective date of the label text read, 20260421.

## Connected pages

- Dofetilide is an antiarrhythmic (FDA established pharmacologic class in RxClass): Antiarrhythmic drugs (`cardio:antiarrhythmic-drugs`)
- FDA label lists maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation or flutter) as an indication: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`) [a claim, not a settled fact; see claim `cardio:claim-fda-dofetilide-label-indications` and its context]
- FDA label lists maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation or flutter) as an indication: Atrial flutter (`cardio:atrial-flutter`) [a claim, not a settled fact; see claim `cardio:claim-fda-dofetilide-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Provenance

Content hash: 717bd69ce8d1e9aa56bb79bc9b5545c4a66467ef33fa76fabceed15d4abd5ebf
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
